This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Kim S, et al. Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea. Applied Health Economics and Health Policy : 2 Mar 2021. Available from: URL: https://doi.org/10.1007/s40258-021-00640-w
Rights and permissions
About this article
Cite this article
Cabozantinib may be cost effective in advanced renal cell carcinoma. PharmacoEcon Outcomes News 874, 10 (2021). https://doi.org/10.1007/s40274-021-7553-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7553-y